PTGX – protagonist therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Do Protagonist Therapeutics' (PTGX) Derisked Drugs Have Blockbuster Potential? [Yahoo! Finance]
J&J Expands New Drug Portfolio With Icotyde's FDA Approval [Yahoo! Finance]
Protagonist Therapeutics (PTGX) had its price target raised by Leerink Partners from $107.00 to $110.00. They now have an "outperform" rating on the stock.
Protagonist Therapeutics (PTGX) had its price target raised by JPMorgan Chase & Co. from $95.00 to $106.00. They now have an "overweight" rating on the stock.
Protagonist Therapeutics (PTGX) had its price target raised by Citigroup Inc. from $115.00 to $125.00. They now have a "buy" rating on the stock.
Form SCHEDULE 13G/A Protagonist Therapeutics Filed by: VANGUARD GROUP INC
Form 144 Protagonist Therapeutics Filed by: SELICK HAROLD E
Form 144 Protagonist Therapeutics Filed by: Ali Asif
Form 144 Protagonist Therapeutics Filed by: MOLINA ARTURO MD
Form 4 Protagonist Therapeutics For: Mar 23 Filed by: PATEL DINESH V PH D
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.